Lifecore Biomedical, Inc.
My sixth write-up is now available for download!
During the last conference call, an unidentified analyst asked LFCR’s management whether double-digit growth is a reasonable expectation beyond FY25. The question went unanswered. The truth is that such growth is achievable even with just the existing late-phase development pipeline and conservative time to commercialization assumptions. A better question would have been how much growth could accelerate if any of the catalysts outlined in this write-up were to materialize. Let’s dive in!
Grab your copies of the report and its accompanying model by clicking the "Download" buttons below. At the end, you’ll also find a list of LFCR write-ups and industry conferences the company will participate in.